List of Excipients in Branded Drug ABACAVIR SULFATE

Generic Drugs Containing ABACAVIR SULFATE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	abacavir sulfate	0378-4105	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	abacavir sulfate	0378-4105	FERRIC OXIDE RED
Mylan Pharmaceuticals Inc	abacavir sulfate	0378-4105	FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc	abacavir sulfate	0378-4105	HYPROMELLOSE

What are the Most Frequently-Used Excipients in ABACAVIR SULFATE?

# Of NDCs	Excipient
5	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
4	FERRIC OXIDE RED
5	FERRIC OXIDE YELLOW

Abacavir Sulfate Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

Abacavir sulfate is an established, off-patent nucleoside reverse transcriptase inhibitor with low formulation complexity and limited opportunity for premium oral products. The strongest commercial opportunities are pediatric taste-masked liquids, globally compliant generic tablets, fixed-dose combinations, excipient substitution, and supply-chain optimization. Patent barriers are generally weak for the standalone active ingredient, while combination-product and regulatory barriers can remain relevant.

What is the pharmaceutical formulation profile of abacavir sulfate?

Abacavir sulfate is the sulfate salt of abacavir, an antiretroviral used in HIV-1 treatment with other antiretroviral agents. The reference product, Ziagen, is marketed as 300 mg tablets and a 20 mg/mL oral solution. Each tablet contains abacavir sulfate equivalent to 300 mg of abacavir. The oral solution contains abacavir equivalent to 20 mg/mL.[1]

Attribute	Commercial relevance
Active ingredient	Abacavir sulfate
Therapeutic class	Nucleoside reverse transcriptase inhibitor
Primary use	Combination antiretroviral therapy for HIV-1
Adult tablet strength	300 mg abacavir equivalent
Oral solution strength	20 mg/mL abacavir equivalent
Main administration route	Oral
Typical adult dose	600 mg daily, as 300 mg twice daily or 600 mg once daily, depending on regimen
Pediatric formulation	Oral solution and weight-based dosing
Key safety requirement	HLA-B*5701 screening and hypersensitivity warning
Reference brand	Ziagen
Major combinations	Abacavir/lamivudine and abacavir/dolutegravir/lamivudine

Abacavir is commonly administered as part of a multidrug regimen. The active pharmaceutical ingredient is therefore only one part of the product value proposition. Tablet size, taste, stability, excipient tolerability, packaging, and combination compatibility have greater commercial significance than novel delivery technology.

What excipients are used in abacavir sulfate tablets and oral solutions?

The reference formulation uses conventional immediate-release excipients. The tablet platform is suitable for direct generic development because it does not require modified-release polymers, lipid systems, enteric coatings, or specialized drug-delivery equipment.

Tablet excipient platform

The Ziagen tablet label identifies conventional excipients including lactose anhydrous, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. The film coating contains standard coating components.[1]

Formulation function	Typical excipient class	Strategic purpose
Diluent	Lactose, microcrystalline cellulose	Tablet mass, compressibility
Disintegrant	Sodium starch glycolate or equivalent	Rapid breakup after administration
Lubricant	Magnesium stearate	Ejection and manufacturing control
Binder	Microcrystalline cellulose or polymeric binder	Tablet strength
Film coating	Hypromellose-based system	Appearance, handling, swallowing
Colorant	Approved iron oxide or other colorant	Product identification
Plasticizer	Triacetin or equivalent	Coating flexibility

A generic developer can generally use a conventional lactose-cellulose-starch-magnesium stearate system. The main development risks are blend uniformity, tablet hardness, disintegration, dissolution, coating performance, and compatibility with the sulfate salt.

Oral solution excipient platform

The reference oral solution uses a sweetened, flavored aqueous system with buffering and preservative components. The label identifies sorbitol, sodium citrate, citric acid, methylparaben, propylparaben, saccharin sodium, and strawberry flavoring among the formulation components.[1]

Formulation function	Typical excipient class	Strategic purpose
Sweetener and bulking agent	Sorbitol	Palatability and viscosity
High-intensity sweetener	Saccharin sodium	Taste correction
Buffer	Citric acid and sodium citrate	pH control
Preservatives	Methylparaben and propylparaben	Microbial protection
Flavor	Strawberry or fruit flavor	Pediatric acceptability
Vehicle	Purified water	Solubilization and administration

The oral solution has more formulation risk than the tablet. Taste, preservative performance, pH drift, microbial quality, precipitation, container compatibility, and dosing-device accuracy all affect product acceptance.

How should an excipient strategy be designed for abacavir sulfate tablets?

The commercial objective for tablets is a low-cost, robust immediate-release formulation that meets comparative dissolution and stability requirements without creating unnecessary excipient complexity.

1. Use a conventional direct-compression or wet-granulation platform

A direct-compression formulation can reduce processing steps and manufacturing cost if the active and excipient particle-size distributions provide adequate flow and content uniformity. Wet granulation may be preferable where the formulation has poor flow, high segregation risk, or insufficient tablet strength.

The preferred screening variables are:

• Abacavir sulfate particle-size distribution
• Lactose grade and spray-dried versus milled morphology
• Microcrystalline cellulose grade
• Sodium starch glycolate concentration
• Magnesium stearate level and blending time
• Tablet compression force
• Film-coat weight gain

Over-lubrication can slow dissolution and reduce tablet strength. Excess disintegrant can increase friability or complicate compression. The formulation should be optimized against dissolution across relevant pH conditions rather than against a single nominal medium.

2. Control excipient-related patient risks

Lactose is commercially convenient but may be unsuitable for some patients with severe lactose intolerance. A lactose-free platform based on microcrystalline cellulose, mannitol, dibasic calcium phosphate, or partially pregelatinized starch could differentiate a generic product in selected markets.

The substitution must preserve:

• Immediate-release dissolution
• Tablet hardness and friability
• Stability under humidity
• Content uniformity
• Manufacturability at commercial scale

A lactose-free product is unlikely to support a major price premium in standard adult HIV markets. Its value is greater where procurement specifications, patient preference, or regional excipient restrictions favor a differentiated formulation.

3. Minimize unnecessary colorants

A plain or lightly colored film coat can simplify regulatory submissions and reduce colorant-related market restrictions. Color-coding remains useful when abacavir is sold alongside multiple antiretroviral tablets, but the commercial benefit should be weighed against global regulatory requirements and coating-supply complexity.

What excipient strategy is most valuable for abacavir sulfate oral solution?

The oral solution offers the clearest formulation opportunity because pediatric HIV treatment depends on accurate, acceptable liquid dosing.

Taste masking

Abacavir oral solution requires taste correction rather than simple sweetening. A practical strategy combines:

• A sugar alcohol such as sorbitol or maltitol
• A high-intensity sweetener
• Fruit flavor systems
• pH optimization
• Viscosity adjustment
• Optional bitterness blockers or ion-exchange resins

Flavor selection should be tested after storage, because flavor perception can change with pH, preservative concentration, and interaction with the active ingredient. Strawberry is established in the reference product, but alternative profiles such as mixed berry or banana may be useful in pediatric markets.

Preservative strategy

Parabens provide a familiar preservation platform, but some markets prefer alternative systems. Potential alternatives include potassium sorbate, sodium benzoate, or benzoic acid, subject to pH and microbial efficacy requirements.

A preservative change can create a meaningful development burden. The sponsor must assess:

• Antimicrobial effectiveness
• Preservative distribution through the container
• Compatibility with dosing syringes
• Stability after opening
• Microbial quality during in-use studies
• Regional regulatory acceptability

A preservative-free multidose solution would require a different container and microbiological control strategy. Unit-dose packaging could reduce preservative requirements but would raise packaging and distribution costs.

Buffer and pH control

Citrate buffering supports a reproducible pH and helps maintain product stability. The target pH should balance chemical stability, taste, preservative efficacy, and compatibility with the packaging system.

A lower-acid formulation may improve taste but reduce preservative performance. A more acidic formulation may improve microbial control while increasing sourness and dental tolerability concerns. The optimum is product-specific and should be established through stability and sensory testing.

Dosing accuracy

A pediatric commercial product should include an oral syringe rather than rely solely on a cup. A 20 mg/mL solution delivers 300 mg in 15 mL, so accurate measurement is important for weight-based dosing. The dosing device should be evaluated for:

• Low-volume accuracy
• Graduation readability
• Compatibility with the solution
• Retention of flavor or preservative components
• Child-resistant packaging requirements

What commercial opportunities exist for abacavir sulfate excipients?

Pediatric liquid reformulation

The highest-value formulation opportunity is an improved pediatric liquid with better palatability, lower sugar content, a robust preservative system, and a dose-measuring syringe. This opportunity is strongest in markets where pediatric HIV treatment remains dependent on liquid antiretroviral products.

Potential positioning includes:

• Improved taste
• Lower sugar or sugar-free formulation
• Reduced dosing volume
• Lactose-free composition
• More convenient packaging
• Improved in-use stability
• Compatibility with pediatric combination therapy

The product must retain bioequivalence or establish its clinical performance through the applicable regulatory pathway. Taste improvement alone does not create regulatory exclusivity, but it can support procurement differentiation and adherence.

Globally compliant generic tablets

A single excipient platform that avoids regionally restricted colorants, animal-derived materials, and unnecessary allergens can reduce the number of market-specific formulations. This is particularly valuable for suppliers serving public-health procurement programs.

Important design choices include:

• Lactose-free versus lactose-containing tablets
• Povidone-free or low-povidone composition
• Avoidance of gelatin and animal-derived excipients
• Colorant selection
• Use of compendial excipients available in multiple regions
• Packaging suitable for hot and humid climates

Fixed-dose combination manufacturing

Abacavir is commercially more relevant in combination products than as a standalone tablet. The most important combinations include:

• Abacavir/lamivudine
• Abacavir/dolutegravir/lamivudine

Combination tablets increase formulation complexity because each active ingredient can have different particle properties, dose ratios, compression behavior, and dissolution requirements. Excipient suppliers can create value through:

• Co-processed diluents
• Low-moisture excipient systems
• Improved flow and segregation control
• High-compression-strength platforms
• Common coating systems for large tablets
• Stability packages for tropical climates

The fixed-dose combination opportunity is constrained by the commercial position of newer integrase inhibitor regimens and by treatment guidelines. Abacavir-containing products remain important but are not the dominant growth segment in many high-income markets.

Alternative dosage forms

Potential but more limited opportunities include:

• Unit-dose oral solutions
• Smaller-volume concentrated liquids
• Dispersible tablets
• Orodispersible tablets
• Sprinkle formulations
• Hospital and pediatric sachets

These products face technical issues involving dose uniformity, taste, moisture sensitivity, packaging, and evidence requirements. A concentrated liquid could reduce shipping volume, but it would increase dosing precision requirements and may intensify taste challenges.

When does abacavir sulfate lose exclusivity?

Standalone abacavir sulfate has lost primary small-molecule patent exclusivity in major markets. Ziagen was approved by the FDA in 1998, and generic abacavir tablets and oral solutions have been marketed in multiple jurisdictions.[1,2]

Exclusivity category	Current commercial position
Standalone active-ingredient patent	Expired in major markets
Reference-product regulatory exclusivity	Expired
Standalone Orange Book protection	Generally no longer the principal barrier
Generic tablet entry	Established
Generic oral solution entry	Established but more formulation-sensitive
Combination-product protection	Must be assessed separately by product and jurisdiction
Data exclusivity in emerging markets	May vary by country

The relevant patent analysis now shifts from the molecule to specific combinations, formulations, manufacturing methods, and jurisdiction-specific listings. A generic company should not assume that expiration of standalone abacavir patents eliminates all risks for an abacavir-containing fixed-dose combination.

What is the FDA regulatory and Orange Book status of abacavir sulfate?

The FDA approved Ziagen under NDA 020977. FDA labeling identifies abacavir tablets and oral solution as immediate-release dosage forms.[1] Generic products are generally approved through abbreviated new drug applications, with comparative pharmaceutical quality and bioequivalence requirements.

The regulatory pathway is comparatively straightforward for conventional tablets. Oral solutions can present more complex pharmaceutical-equivalence questions involving concentration, excipient differences, preservative systems, flavoring, and dosing devices.

Regulatory issue	Tablet	Oral solution
Immediate-release dosage form	Yes	Yes
Bioequivalence focus	Dissolution and systemic exposure	Concentration, exposure, excipient and device comparability
Taste evaluation	Limited regulatory importance	Commercially important
Microbial preservation	Routine solid-dose control	Critical
Packaging interaction	Moderate	High
Pediatric-use relevance	Moderate	High

Abacavir products also carry a clinically significant hypersensitivity warning. HLA-B*5701 screening is required before starting therapy under the product labeling, and patients with a positive result should not receive abacavir.[1] This safety issue affects labeling, clinical workflow, and market acceptance but is not an excipient-driven differentiation opportunity.

Which companies are challenging or competing with abacavir sulfate products?

Competition comes from generic manufacturers and from alternative antiretroviral regimens rather than from a single patent challenger.

Generic competition

Generic abacavir products have been marketed by multiple manufacturers, including regional and multinational suppliers. The competitive basis is typically:

• Lowest acquisition cost
• WHO or national regulatory approval
• Reliable supply
• Tropical stability
• Combination-product availability
• Pediatric presentation
• Public-sector procurement eligibility

Excipient strategy can support a tender advantage, but active-ingredient cost, manufacturing scale, quality history, and supply reliability usually determine the largest share of commercial value.

Therapeutic competition

Abacavir competes with tenofovir-based and other nucleoside-backbone regimens. Dolutegravir-based regimens have shifted treatment practice toward combinations that may not contain abacavir. The result is a declining strategic role for standalone abacavir despite continued demand in selected patients and markets.

Abacavir remains relevant where:

• Renal or bone considerations affect regimen selection
• Existing patients are stable on abacavir-containing therapy
• Pediatric formulations are required
• Local guidelines retain abacavir combinations
• Fixed-dose products are available at competitive prices

What patent barriers affect abacavir sulfate formulation opportunities?

Standalone formulation patents

A conventional abacavir sulfate tablet using standard excipients is unlikely to support meaningful new patent protection unless it has a narrow, technically demonstrated formulation feature. Possible patentable areas include:

• Specific taste-masking systems
• Stabilized oral solutions
• Low-volume pediatric formulations
• Novel dispersible or orodispersible tablets
• Container-closure systems linked to stability
• Manufacturing processes that materially improve quality

A patent claim based only on routine excipient substitution is vulnerable to obviousness and lack-of-technical-effect challenges.

Method-of-use patents

Method-of-use claims may cover particular treatment populations or dosing regimens, but their commercial value is limited when the active ingredient is already used broadly in combination therapy. Labeling and induced-infringement issues require product-specific legal analysis.

Combination-product patents

Abacavir/lamivudine and abacavir/dolutegravir/lamivudine products require separate patent reviews. The relevant rights may concern:

• Specific active-ingredient combinations
• Ratios and strengths
• Once-daily dosing
• Stabilized compositions
• Manufacturing methods
• Treatment methods

A generic company may have a lower-risk pathway for standalone abacavir than for a branded fixed-dose combination.

How strong is the abacavir sulfate patent estate?

The standalone estate is weak from a commercial-entry perspective because the core compound and reference product have long been established. The remaining value is concentrated in product-specific improvements and combination products.

Estate component	Relative strength
Core abacavir compound	Low for new entry barriers
Sulfate salt as a conventional product form	Low
Standard immediate-release tablet	Low
Pediatric taste-masked solution	Moderate if technically differentiated
Novel device or packaging system	Moderate
Abacavir-containing fixed-dose combinations	Product- and jurisdiction-dependent
Manufacturing process claims	Dependent on claim scope and proof of non-obviousness

The strongest commercial strategy is therefore not to rely on patent exclusivity. It is to combine low-cost manufacturing with formulation quality, pediatric usability, procurement access, and reliable supply.

What generic launch scenarios exist for abacavir sulfate?

Scenario 1: Low-cost adult tablet

This is the lowest-risk entry model. The developer uses a conventional immediate-release formulation, standard packaging, and a broad excipient supply base. Price competition is intense, and margins depend on scale.

Scenario 2: Differentiated pediatric solution

This model targets taste, dosing convenience, and in-use stability. It requires more development work but offers a clearer product-level value proposition than a standard tablet.

Scenario 3: Fixed-dose combination

This model can improve adherence and procurement attractiveness. It also introduces more complex patent, bioequivalence, manufacturing, and supply-chain issues.

Scenario 4: Tropicalized global product

A formulation and package designed for high heat and humidity can support public-sector and emerging-market sales. Priorities include moisture protection, robust bottle and closure systems, preservative stability, and long-term assay control.

How does abacavir compare with competing antiretroviral formulation opportunities?

Product opportunity	Formulation complexity	Patent risk	Commercial differentiation
Abacavir tablet	Low	Low	Low
Abacavir oral solution	Moderate	Low to moderate	Moderate
Abacavir/lamivudine tablet	Moderate	Product-specific	Moderate
Abacavir/dolutegravir/lamivudine tablet	High	Higher than standalone	Moderate to high
Tenofovir-based tablet	Moderate	Product-specific	High market competition
Long-acting injectable antiretroviral	High	High	High

Abacavir is attractive for cost-focused oral formulation programs, but it is less attractive for large investments in novel delivery technology. The best return is more likely to come from manufacturing efficiency and pediatric product quality than from advanced drug delivery.

What revenue exposure and licensing opportunities exist?

No standalone current revenue figure should be attributed to Ziagen without a defined reporting period and product-level disclosure. GlaxoSmithKline transferred or reorganized parts of its HIV business through ViiV Healthcare, making company-level revenue attribution dependent on reporting scope.[3]

Commercial opportunities include:

• Licensing a pediatric formulation to regional HIV manufacturers
• Supplying excipient systems for generic abacavir tablets
• Contract development of oral solutions
• Co-development of abacavir-containing fixed-dose combinations
• Technology transfer for tropical-stable packaging
• Distribution partnerships in public-health markets

Licensing value is higher for a differentiated pediatric or combination product than for a standard adult tablet. A generic tablet license is primarily a market-access and manufacturing transaction, not an exclusivity transaction.

Key Takeaways

• Abacavir sulfate is an established, off-patent oral antiretroviral with low standalone formulation complexity.
• Conventional immediate-release tablets offer limited differentiation and face substantial price competition.
• Pediatric oral solution development is the strongest excipient-led opportunity.
• Taste masking, preservative selection, pH control, and dosing-device accuracy are the critical liquid-formulation variables.
• Lactose-free, low-sugar, and tropical-stable products can improve procurement positioning but are unlikely to create large premium pricing.
• Fixed-dose combinations have greater commercial relevance than standalone abacavir but require separate patent and regulatory analysis.
• Patent value is concentrated in specific formulations, combinations, manufacturing processes, and packaging systems.
• Excipient suppliers can compete through co-processed materials, low-moisture systems, global regulatory compliance, and manufacturing consistency.
• Abacavir's clinical safety requirements, including HLA-B*5701 screening, remain central to labeling but do not create an excipient opportunity.

FAQs

Is abacavir sulfate suitable for a sustained-release formulation?

Abacavir is commercially established as an immediate-release product. A sustained-release formulation would face limited commercial justification because effective once-daily immediate-release dosing is already available in relevant regimens.

Can abacavir oral solution be reformulated without sorbitol?

Yes. Sorbitol can be replaced with other sweeteners or bulking agents, but the reformulation must address taste, viscosity, osmolarity, stability, microbial control, and bioequivalence requirements.

Does abacavir sulfate require a special tablet coating?

No. A conventional immediate-release film coat is generally adequate. The coating should support identification, mechanical protection, swallowability, and stability without delaying disintegration.

Is a fixed-dose abacavir combination more valuable than standalone abacavir?

Usually. Combination products improve adherence and procurement efficiency, but they face more complex formulation development, patent review, and competitive pressure from non-abacavir regimens.

What is the best excipient innovation target for abacavir sulfate?

The best target is a pediatric liquid platform that improves bitterness control, reduces sugar or dosing volume, maintains preservative efficacy, and provides an accurate oral syringe.

References

1. U.S. Food and Drug Administration. (2023). Ziagen (abacavir sulfate) tablets and oral solution: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition.
3. ViiV Healthcare. (2024). Annual report and corporate information.
4. World Health Organization. (2023). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach.
5. U.S. Department of Health and Human Services. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.